# The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.

> **NCT04632862** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 140 (actual)

## Conditions studied

- T2DM (Type 2 Diabetes Mellitus)

## Interventions

- **DRUG:** DWP16001

## Key facts

- **NCT ID:** NCT04632862
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-11
- **Primary completion:** 2021-11-25
- **Final completion:** 2021-11-25
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2022-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04632862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04632862, "The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04632862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*